Skip to main content Accessibility help
×
Home

Early-Onset Familial Alzheimer's Disease (EOFAD)

  • Liyong Wu (a1) (a2) (a3), Pedro Rosa-Neto (a1) (a2) (a4), Ging-Yuek R. Hsiung (a5), A. Dessa Sadovnick (a5) (a6), Mario Masellis (a7) (a8), Sandra E. Black (a7), Jianping Jia (a3) and Serge Gauthier (a1)...

Abstract

Early-onset familial Alzheimer's disease (EOFAD) is a condition characterized by early onset dementia (age at onset < 65 years) and a positive family history for dementia. To date, 230 mutations in presenilin (PS1, PS2) and amyloid precursor protein (APP) genes have been identified in EOFAD. The mutations within these three genes (PS1/PS2/APP) affect a common pathogenic pathway in APP synthesis and proteolysis, which lead to excessive production of amyloid β. Compared with sporadic Alzheimer's disease (AD), EOFAD has some distinctive features including early age at onset, positive familial history, a variety of non-cognitive neurological symptoms and signs, and a more aggressive course. There is marked phenotypic heterogeneity among different mutations of EOFAD. Studies in presymptomatic mutation carriers reveal biomarkers abnormalities. EOFAD diagnosis is based on clinical and family history, neurological symptoms and examination, biomarker features, as well as genotyping in some cases. New therapeutic agents targeting amyloid formation may benefit EOFAD individuals.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Early-Onset Familial Alzheimer's Disease (EOFAD)
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Early-Onset Familial Alzheimer's Disease (EOFAD)
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Early-Onset Familial Alzheimer's Disease (EOFAD)
      Available formats
      ×

Copyright

Corresponding author

McGill Centre for Studies in Aging (MCSA), McGill University, 6825, Boul. LaSalle Blvd., Montreal, QC, H4H 1R3, Canada. Email: serge.gauthier@mcgill.ca

References

Hide All
1.Feldman, RG, Glaser, GH, Chandler, KA, Levy, LL.Familial Alzheimers disease. Neurology. 1963;13:81124.
2.Rossor, MN, Fox, NC, Mummery, CJ, Schott, JM, Warren, JD.The diagnosis of young-onset dementia. Lancet Neurol. 2010;9:793806.
3.Campion, D, Dumanchin, C, Hannequin, D, et al.Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet. 1999;65:66470.
4.Lleo, A, Blesa, R, Queralt, R, et al.Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain. Arch Neurol. 2002;59:175963.
5.Janssen, JC, Beck, JA, Campbell, TA, et al.Early onset familial Alzheimer’s disease: mutation frequency in 31 families. Neurology. 2003;60:2359.
6.Clarimon, J, Djaldetti, R, Lleo, A, et al.Whole genome analysis in a consanguineous family with early onset Alzheimer’s disease. Neurobiol Aging. 2009;30:198691.
7.Bateman, RJ, Aisen, PS, De Strooper, B, et al.Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther. 2011;2:35.
8.Albert, MS, DeKosky, ST, Dickson, D, et al.The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:2709.
9.McKhann, GM, Knopman, DS, Chertkow, H, et al.The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:2639.
10.Sperling, RA, Aisen, PS, Beckett, LA, et al.Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:28092.
11.St. George-Hyslop, PH, Tanzi, RE, Polinsky, RJ, et al.The genetic-defect causing familial Alzheimers-disease maps on chromosome-21. Science. 1987;235:88590.
12.Goate, A, Chartierharlin, MC, Mullan, M, et al.Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimers-disease. Nature. 1991;349:7046.
13.St. George-Hyslop, P, Haines, J, Rogaev, E, et al.Genetic-evidence for a novel familial Alzheimers-disease locus on chromosome-14. Nat Genet. 1992;2:3304.
14.Mullan, M, Houlden, H, Windelspecht, M, et al.A locus for familial early-onset Alzheimers-disease on the long arm of chromosome 14, proximal to the alpha-1-antichymotrypsin gene. Nat Genet. 1992;2:3402.
15.Schellenberg, GD, Bird, TD, Wijsman, EM, et al.Genetic-linkage evidence for a familial Alzheimers-disease locus on chromosome-14. Science. 1992;258:66871.
16.Sherrington, R, Rogaev, EI, Liang, Y, et al.Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature. 1995;375:75460.
17.Rogaev, EI, Sherrington, R, Rogaeva, EA, et al.Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature. 1995;376:7758.
18.Levylahad, E, Wasco, W, Poorkaj, P, et al.Candidate gene for the chromosome-1 familial Alzheimers-disease locus. Science. 1995;269:9737.
19.Ikeuchi, T, Kaneko, H, Miyashita, A, et al.Mutational analysis in early-onset familial dementia in the Japanese population. The role of PSEN1 and MAPT R406W mutations. Dement Geriatr Cogn Disord. 2008;26:439.
20.Kowalska, A, Pruchnik-Wolinska, D, Florczak, J, et al.Genetic study of familial cases of Alzheimer’s disease. Acta Biochim Pol. 2004;51:24552.
21.de la Torre, JC.Three postulates to help identify the cause of Alzheimer’s disease. J Alzheimers Dis. 2011;24:65768.
22.Trojanowski, JQ, Lee, VM.Phosphorylation of paired helical filament tau in Alzheimer’s disease neurofibrillary lesions: focusing on phosphatases. FASEB J. 1995;9:15706.
23.Glass, CK, Saijo, K, Winner, B, Marchetto, MC, Gage, FH.Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:91834.
24.Hardy, J, Selkoe, DJ.The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:3536.
25.Bettens, K, Sleegers, K, Van Broeckhoven, C.Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet. 2010;19:R4R11.
26.Esler, WP, Wolfe, MS.A portrait of Alzheimer secretases-new features and familiar faces. Science. 2001;293:144954.
27.Citron, M, Oltersdorf, T, Haass, C, et al.Mutation of the beta-amyloid precursor protein in familial Alzheimers-disease increases beta-protein production. Nature. 1992;360:6724.
28.Suzuki, N, Cheung, TT, Cai, XD, et al.An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 1994;264:133640.
29.Steiner, H.Uncovering gamma-secretase. Curr Alzheimer Res. 2004;1:17581.
30.Shepherd, C, McCann, H, Halliday, GM.Variations in the neuropathology of familial Alzheimer’s disease. Acta Neuropathol. 2009;118:3752.
31.Gomez-Isla, T, Growdon, WB, McNamara, MJ, et al.The impact of different presenilin 1 and presenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer’s disease brain: evidence for other phenotype-modifying factors. Brain. 1999;122(Pt 9):170919.
32.Lleo, A, Berezovska, O, Growdon, JH, Hyman, BT.Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am J Geriatr Psychiatry. 2004;12:14656.
33.Karlstrom, H, Brooks, WS, Kwok, JB, et al.Variable phenotype of Alzheimer’s disease with spastic paraparesis. J Neurochem. 2008;104:57383.
34.Maarouf, CL, Daugs, ID, Spina, S, et al.Histopathological and molecular heterogeneity among individuals with dementia associated with presenilin mutations. Mol Neurodegener. 2008;3:20.
35.Brooks, WS, Kwok, JB, Kril, JJ, et al.Alzheimer’s disease with spastic paraparesis and ‘cotton wool’ plaques: two pedigrees with PS-1 exon 9 deletions. Brain. 2003;126:78391.
36.Verkkoniemi, A, Kalimo, H, Paetau, A, et al.Variant Alzheimer disease with spastic paraparesis: neuropathological phenotype. J Neuropathol Exp Neurol. 2001;60:48392.
37.Dumanchin, C, Tournier, I, Martin, C, et al.Biological effects of four PSEN1 gene mutations causing Alzheimer disease with spastic paraparesis and cotton wool plaques. Hum Mutat. 2006;27:1063.
38.Houlden, H, Baker, M, McGowan, E, et al.Variant Alzheimer’s disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-beta concentrations. Ann Neurol. 2000;48:8068.
39.Sleegers, K, Brouwers, N, Gijselinck, I, et al.APP duplication is sufficient to cause early onset Alzheimer’s dementia with cerebral amyloid angiopathy. Brain. 2006;129:297783.
40.Rovelet-Lecrux, A, Hannequin, D, Raux, G, et al.APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38:246.
41.Dermaut, B, Kumar-Singh, S, De Jonghe, C, et al.Cerebral amyloid angiopathy is a pathogenic lesion in Alzheimer’s disease due to a novel presenilin 1 mutation. Brain. 2001;124:238392.
42.Snider, BJ, Norton, J, Coats, MA, et al.Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch Neurol. 2005;62:182130.
43.Singleton, AB, Hall, R, Ballard, CG, et al.Pathology of early-onset Alzheimer’s disease cases bearing the Thr113-114ins presenilin-1 mutation. Brain. 2000;123 Pt 12:246774.
44.Mann, DM, Pickering-Brown, SM, Takeuchi, A, Iwatsubo, T.Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer’s disease. Am J Pathol. 2001;158:216575.
45.Hendriks, L, van Duijn, CM, Cras, P, et al.Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet. 1992;1:21821.
46.Rossi, G, Giaccone, G, Maletta, R, et al.A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene. Neurology. 2004;63:91012.
47.Piscopo, P, Marcon, G, Piras, MR, et al.A novel PSEN2 mutation associated with a peculiar phenotype. Neurology. 2008;70:154954.
48.Ishikawa, A, Piao, YS, Miyashita, A, et al.A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer’s disease. Ann Neurol. 2005;57:42934.
49.Balasa, M, Gelpi, E, Antonell, A, et al.Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology. 2011;76:17205.
50.Mullan, M, Houlden, H, Crawford, F, Kennedy, A, Rogues, P, Rossor, M.Age-of-onset in familial early-onset Alzheimers-disease correlates with genetic etiology. Am J Med Genet. 1993;48:12930.
51.Wijsman, EM, Daw, EW, Yu, X, et al.APOE and other loci affect age-at-onset in Alzheimer’s disease families with PS2 mutation. Am J Med Genet B Neuropsychiatr Genet. 2005;132B:1420.
52.Jacobs, D, Sano, M, Marder, K, et al.Age at onset of Alzheimer’s disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology. 1994;44:121520.
53.Koedam, EL, Lauffer, V, van der Vlies, AE, van der Flier, WM, Scheltens, P, Pijnenburg, YA.Early-versus late-onset Alzheimer’s disease: more than age alone. J Alzheimers Dis. 2010;19:14018.
54.Bird, TD, Sumi, SM, Nemens, EJ, et al.Phenotypic heterogeneity in familial Alzheimers-disease - a study of 24 kindreds. Ann Neurol. 1989;25:1225.
55.Larner, AJ, Doran, M.Clinical phenotypic heterogeneity of Alzheimer’s disease associated with mutations of the presenilin-1 gene. J Neurol. 2006;253:13958.
56.Lopera, F, Ardilla, A, Martinez, A, et al.Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA. 1997;277:7939.
57.Rudzinski, LA, Fletcher, RM, Dickson, DW, et al.Early onset familial Alzheimer disease with spastic paraparesis, dysarthria, and seizures and N135S mutation in PSEN1. Alzheimer Dis Assoc Dis. 2008;22:299307.
58.Jayadev, S, Leverenz, JB, Steinbart, E, et al.Alzheimer’s disease phenotypes and genotypes associated with mutations in presenilin 2. Brain. 2010;133:114354.
59.Kennedy, AM, Newman, S, McCaddon, A, et al.Familial Alzheimers-disease - a pedigree with a mis-sense mutation in the amyloid precursor protein gene (amyloid precursor protein 717 valine -> glycine). Brain. 1993;116:30924.
60.Cabrejo, L, Guyant-Marechal, L, Laquerriere, A, et al.Phenotype associated with APP duplication in five families. Brain. 2006;129:296676.
61.Jia, JP, Xu, E, Shao, YK, Jia, JM, Sun, YX, Li, D.One novel presenilin-1 gene mutation in a Chinese pedigree of familial Alzheimer’s disease. J Alzheimers Dis. 2005;7:11924.
62.Janssen, JC, Hall, M, Fox, NC, et al.Alzheimer’s disease due to an intronic presenilin-1 (PSEN1 intron 4) mutation: a clinicopathological study. Brain. 2000;123(Pt 5):894907.
63.Acosta-Baena, N, Sepulveda-Falla, D, Lopera-Gomez, CM, et al.Predementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer’s disease: a retrospective cohort study. Lancet Neurol. 2011;10:21320.
64.Filley, CM, Rollins, YD, Anderson, CA, et al.The genetics of very early onset Alzheimer disease. Cogn Behav Neurol. 2007;20:14956.
65.Arai, N, Kishino, A, Takahashi, Y, et al.Familial cases presenting very early onset autosomal dominant Alzheimer’s disease with I143T in presenilin-1 gene: implication for genotype-phenotype correlation. Neurogenetics. 2008;9:657.
66.Goldman, JS, Reed, B, Gearhart, R, Kramer, JH, Miller, BL.Very early-onset familial Alzheimer’s disease: a novel presenilin 1 mutation. Int J Geriat Psychiatry. 2002;17:64951.
67.Ataka, S, Tomiyama, T, Takuma, H, et al.A novel presenilin-1 mutation (Leu85Pro) in early-onset Alzheimer disease with spastic paraparesis. Arch Neurol. 2004;61:17736.
68.Jimenez-Escrig, A, Rabano, A, Guerrero, C, et al.New V272A presenilin 1 mutation with very early onset subcortical dementia and parkinsonism. Eur J Neurol. 2004;11:6639.
69.Lampe, TH, Bird, TD, Nochlin, D, et al.Phenotype of chromosome 14-linked familial Alzheimers-disease in a large kindred. Ann Neurol. 1994;36:36878.
70.Gomez-Tortosa, E, Barquero, S, Baron, M, et al.Clinical-genetic correlations in familial Alzheimer’s disease caused by presenilin 1 mutations. J Alzheimers Dis. 2010;19:87384.
71.Crook, R, Verkkoniemi, A, Perez-Tur, J, et al.A variant of Alzheimer’s disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med. 1998;4:4525.
72.Sodeyama, N, Iwata, T, Ishikawa, K, et al.Very early onset Alzheimer’s disease with spastic paraparesis associated with a novel presenilin 1 mutation (Phe237Ile). J Neurol Neurosurg Psychiatry. 2001;71:5567.
73.Ezquerra, M, Lleo, A, Castellvi, M, et al.A novel mutation in the PSEN2 gene (T430M) associated with variable expression in a family with early-onset Alzheimer disease. Arch Neurol. 2003;60:114951.
74.Cras, P, van Harskamp, F, Hendriks, L, et al.Presenile Alzheimer dementia characterized by amyloid angiopathy and large amyloid core type senile plaques in the APP 692Ala->Gly mutation. Acta Neuropathol. 1998;96:25360.
75.Roks, G, Van Harskamp, F, De Koning, I, et al.Presentation of amyloidosis in carriers of the codon 692 mutation in the amyloid precursor protein gene (APP692). Brain. 2000;123(Pt 10):213040.
76.Brooks, WS, Kwok, JB, Halliday, GM, et al.Hemorrhage is uncommon in new Alzheimer family with Flemish amyloid precursor protein mutation. Neurology. 2004;63:161317.
77.Levy, E, Carman, MD, Fernandez-Madrid, IJ, et al.Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science. 1990;248:11246.
78.Basun, H, Bogdanovic, N, Ingelsson, M, et al.Clinical and neuropathological features of the Arctic APP gene mutation causing early-onset Alzheimer disease. Arch Neurol. 2008;65:499505.
79.Grabowski, TJ, Cho, HS, Vonsattel, JP, Rebeck, GW, Greenberg, SM.Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol. 2001;49:697705.
80.Bornebroek, M, Haan, J, Maat-Schieman, ML, Van Duinen, SG, Roos, RA.Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): I-A review of clinical, radiologic and genetic aspects. Brain Pathol. 1996;6:11114.
81.Kasuga, K, Shimohata, T, Nishimura, A, et al.Identification of independent APP locus duplication in Japanese patients with early-onset Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80:10502.
82.Ridha, BH, Barnes, J, Bartlett, JW, et al.Tracking atrophy progression in familial Alzheimer’s disease: a serial MRI study. Lancet Neurol. 2006;5:82834.
83.Quiroz, YT, Budson, AE, Celone, K, et al.Hippocampal hyperactivation in presymptomatic familial Alzheimer’s disease. Ann Neurol. 2010;68:86575.
84.Chan, D, Janssen, JC, Whitwell, JL, et al.Change in rates of cerebral atrophy over time in early-onset Alzheimer’s disease: longitudinal MRI study. Lancet. 2003;362:11212.
85.Wu, L, Rosa-Neto, P, Gauthier, S.Use of biomarkers in clinical trials of Alzheimer disease: from concept to application. Mol Diagn Ther. 2011;15:31325.
86.Klunk, WE, Price, JC, Mathis, CA, et al.Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27:617484.
87.Villemagne, VL, Ataka, S, Mizuno, T, et al.High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol. 2009;66:153744.
88.Knight, WD, Okello, AA, Ryan, NS, et al.Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain. 2011;134:293300.
89.Remes, AM, Laru, L, Tuominen, H, et al.Carbon 11-labeled Pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol. 2008;65:5404.
90.Mosconi, L, Sorbi, S, de Leon, MJ, et al.Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer’s disease. J Nucl Med. 2006;47:177886.
91.Ringman, JM, Medina, LD, Braskie, M, et al.Effects of risk genes on BOLD activation in presymptomatic carriers of familial Alzheimer’s disease mutations during a novelty encoding task. Cereb Cortex. 2011;21:87783.
92.Fox, NC, Warrington, EK, Freeborough, PA, et al.Presymptomatic hippocampal atrophy in Alzheimer’s disease. A longitudinal MRI study. Brain. 1996;119(Pt 6):20017.
93.Schott, JM, Fox, NC, Frost, C, et al.Assessing the onset of structural change in familial Alzheimer’s disease. Ann Neurol. 2003;53:1818.
94.Ringman, JM, O’Neill, J, Geschwind, D, et al.Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer’s disease mutations. Brain. 2007;130:176776.
95.Moonis, M, Swearer, JM, Dayaw, MP, et al.Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. Neurology. 2005;65:3235.
96.Ringman, JM, Younkin, SG, Pratico, D, et al.Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology. 2008;71:8592.
97.Rohrer, JD, Guerreiro, R, Vandrovcova, J, et al.The heritability and genetics of frontotemporal lobar degeneration. Neurology. 2009;73:14516.
98.Piguet, O, Hornberger, M, Mioshi, E, Hodges, JR.Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol. 2011;10:16272.
99.Dejesus-Hernandez, M, Mackenzie, IR, Boeve, BF, et al.Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:24556.
100.Ren ton, AE, Majounie, E, Waite, A, et al.A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:25768.
101.Panegyres, PK, Frencham, K.Course and causes of suspected dementia in young adults: a longitudinal study. Am J Alzheimers Dis Other Dement. 2007;22:4856.
102.Laforce, R Jr., Buteau, JP, Paquet, N, Verret, L, Houde, M, Bouchard, RW.The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: a retrospective memory clinic study. Am J Alzheimers Dis Other Dement. 2010;25:32432.
103.Rabinovici, GD, Rosen, HJ, Alkalay, A, et al.Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77:203442.
104.Gambetti, P, Parchi, P, Chen, SG.Hereditary Creutzfeldt-Jakob disease and fatal familial insomnia. Clin Lab Med. 2003;23:4364.
105.Dichgans, M, Mayer, M, Uttner, I, et al.The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol. 1998;44:7319.
106.Joutel, A, Corpechot, C, Ducros, A, et al.Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383:70710.
107.Raux, G, Guyant-Marechal, L, Martin, C, et al.Molecular diagnosis of autosomal dominant early onset Alzheimer’s disease: an update. J Med Genet. 2005;42:7935.
108.Guerreiro, RJ, Baquero, M, Blesa, R, et al.Genetic screening of Alzheimer’s disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiol Aging. 2010;31:72531.
109.Goldman, JS, Hou, CE.Early-onset Alzheimer disease: when is genetic testing appropriate? Alzheimer Dis Assoc Disord. 2004;18:657.
110.Butler, R, Dwosh, E, Beattie, BL, et al.Genetic counseling for early-onset familial Alzheimer disease in large Aboriginal kindred from a remote community in British Columbia: unique challenges and possible solutions. J Genet Couns. 2011;20:13642.
111.Patterson, C, Feightner, JW, Garcia, A, Hsiung, GY, MacKnight, C, Sadovnick, AD.Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ. 2008;178:54856.
112.Bird, TD, Bennett, RL.Why do DNA testing? Practical and ethical implications of new neurogenetic tests. Ann Neurol. 1995;38:1416.
113.Steinbart, EJ, Smith, CO, Poorkaj, P, Bird, TD.Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia. Arch Neurol. 2001;58:182831.
114.Fortea, J, Llado, A, Clarimon, J, et al.PICOGEN: Five years experience with a genetic counselling program for dementia. Neurologia. 2011;26:1439.
115.Mangialasche, F, Solomon, A, Winblad, B, Mecocci, P, Kivipelto, M.Alzheimer’s disease: clinical trials and drug development. Lancet Neurol. 2010;9:70216.
116.Ostrowitzki, S, Deptula, D, Thurfjell, L, et al.Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012; vol 69, pp. 198207.
117.Aisen, PS, Andrieu, S, Sampaio, C, et al.Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2011;76:2806.
118.Cummings, JL, Doody, R, Clark, C.Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology. 2007;69:162234.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed